6IO Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
International GrowthSustained double-digit international growth indicates expanding geographic reach and durable demand beyond the U.S. market. Continued contribution from overseas channels can diversify revenue, improve scale, and reduce reliance on mature domestic sales over the next several quarters.
New Product AdoptionEarly adoption of Voxi and Aurora demonstrates that Inogen is refreshing its product portfolio and generating incremental demand. A growing installed base of newer devices can support future revenue expansion, strengthen customer relevance, and improve product mix.
Balance Sheet FlexibilityVery low leverage gives Inogen financial flexibility while it works through its operating turnaround. A conservatively funded balance sheet reduces interest and refinancing pressure, preserves capacity to invest in products and channels, and provides resilience if execution takes longer.
Bears Say
Persistent Cash BurnNegative operating and free cash flow show that the business has not yet become consistently self-funding. Continued cash consumption could limit investment flexibility, increase reliance on existing liquidity, and weaken the durability of the turnaround if earnings improvement stalls.
U.S. Channel PressureThe shift away from DTC and traditional rentals can pressure revenue quality and channel economics because growth in B2B is not fully replacing declining direct activity. Persistent mix pressure may constrain topline growth and limit operating leverage.
Regulatory Reimbursement UncertaintyUncertain reimbursement and regulatory timing can delay commercialization and reduce the pace at which newer respiratory products reach patients. These constraints may lengthen investment cycles, make demand less predictable, and defer the contribution of potential growth initiatives.
Inogen News
6IO FAQ
What was Inogen’s price range in the past 12 months?
Currently, no data Available
What is Inogen’s market cap?
Inogen’s market cap is CHF159.17M.
When is Inogen’s upcoming earnings report date?
Inogen’s upcoming earnings report date is Nov 05, 2026 which is in 7 days.
How were Inogen’s earnings last quarter?
Inogen released its earnings results on Aug 06, 2026. The company reported -CHF0.116 earnings per share for the quarter, beating the consensus estimate of -CHF0.127 by CHF0.011.
Is Inogen overvalued?
According to Wall Street analysts Inogen’s price is currently Undervalued.
Does Inogen pay dividends?
Inogen does not currently pay dividends.
What is Inogen’s EPS estimate?
Inogen’s EPS estimate is -0.12.
How many shares outstanding does Inogen have?
Inogen has 26,538,338 shares outstanding.
What happened to Inogen’s price movement after its last earnings report?
Inogen reported an EPS of -CHF0.116 in its last earnings report, beating expectations of -CHF0.127. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Inogen?
Currently, no hedge funds are holding shares in CH:6IO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inogen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF10.75 (― Upside)
CHF10.75 (― Upside)
Blogger Sentiment
Bullish
CH:6IO Sentiment 80%
Sector Average 65%
Sector Average 65%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-15.00%
12-Months-Change
Fundamentals
Return on Equity
-13.17%
Trailing 12-Months
Asset Growth
-8.48%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Inogen
Inogen, Inc. operates as a medical technology enterprise dedicated to designing, fabricating, and distributing oxygen concentration equipment. These cutting-edge devices are engineered to provide continuous oxygen support for patients managing persistent respiratory conditions. The company's diverse product range features the popular portable Inogen One, which efficiently draws oxygen from the surrounding atmosphere to offer an independent supply, alongside stationary Inogen At Home concentrators, Tidal Assist Ventilators, and various associated accessories. Inogen serves a broad clientele, including individual patients, medical professionals, and insurance providers, both domestically in the United States and globally. Furthermore, the company facilitates direct equipment rentals to patients. Founded in 2001, Inogen, Inc. is headquartered in Goleta, California.
6IO Company Deck
6IO Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted clear commercial and product progress — notably strong international revenue growth (+15% YoY), continued POC unit expansion (>12% YoY), early traction for new products (Voxi shipments >5,000; Aurora account count doubled), margin improvement (adjusted gross margin +65 bps) and a raised adjusted EBITDA outlook. Offsetting these positives are ongoing headwinds in the U.S. DTC channel (U.S. sales -2% YoY), a 12% decline in rental revenue, a downward revision to full-year revenue guidance (midpoint reduction of ~ $11.5M), and continued dependency on distributor purchase timing and reimbursement/regulatory milestones. Overall the company shows momentum in strategic growth areas and improved unit economics, but macro and channel mix pressures keep near-term top-line growth constrained.View all CH:6IO earnings summaries